The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of BIIB067 in adults with ALS and confirmed superoxide dismutase 1 (SOD1) mutation. BIIB067 will be administered via lumbar punctures over a 24-week treatment period (i.e. 3 loading doses administered approximately once every 2 weeks, followed by 5 maintenance doses administered approximately once every 4 weeks). Overall, participants will be in the research study for about 32 weeks.
Principal Investigator: Shafeeq Ladha, MD